5:28 PM
 | 
Jan 28, 2013
 |  BC Extra  |  Company News

FDA accepts Lemtrada sBLA

FDA accepted for review an sBLA from Genzyme Corp. for Lemtrada alemtuzumab to treat relapsing multiple sclerosis. The PDUFA date is in 2H13, but the exact date is not disclosed. Last...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >